Current Clinical Research Projects at Our Clinic
Alector Inc.
Protocol: AL002-2
Patients: 50-85 years old
Diagnostic: Early Alzheimer’s disease
Agent: AL002
Intravenous Administration Every 4 Weeks
Enrollment: OPEN
Athira Pharma Inc.
Protocol: ATH-1017-AD-0201
Patients: 55-85 years old
Diagnostic: Probable Mild-Moderate AD
Agent: ATH-1017
Daily Subcutaneous Injection
Enrollment: OPEN
Cassava Sciences Inc.
Protocol: PTI-125-06
Patients: 50-87 years old
Diagnostic: Alzheimer’s disease (Stage 4 or 5)
Agent: Simufilam (PTI-125)
Twice Daily Oral Administration
Enrollment: OPEN
Eli Lilly and Company
Protocol: I5T-MC-AACM
Patients: 65-80 years old
Diagnostic: Prodromal/Asymptomatic AD
Agent: Donanemab
Intravenous Administration Every 4 Weeks
Enrollment: OPEN
Novo Nordisk
Protocol: NN6535-4730
Patients: 55-85 years old
Diagnostic: Early Alzheimer’s disease
Agent: Semaglutide
Once Daily Oral Administration
Enrollment: OPEN
Alzheon Inc.
Protocol: ALZ-801-AD301
Patients: 50-80 years old
Diagnostic: Early Alzheimer’s disease
Agent: ALZ-801
Twice Daily Oral Administration
Enrollment: Closed
Athira Pharma Inc.
Protocol: ATH-1017-AD-0202
Patients: 55-85 years old
Diagnostic: Probable Mild-Moderate AD
Agent: ATH-1017
Daily Subcutaneous Injection
Enrollment: Closed
Athira Pharma Inc.
Protocol: ATH-1017-PD-0201
Patients: 40-85 years old
Diagnostic: Parkinson’s or Lewy Body disease
Agent: ATH-1017
Daily Subcutaneous Injection
Enrollment: Closed
Eli Lilly and Company
Protocol: I5T-MC-AACI
Patient: 60-85 years old
Diagnostic: Prodromal or Mild AD Dementia
Agent: Donanemab
Intravenous Administration Every 4 Weeks
Enrollment: Closed
Novo Nordisk
Protocol: NN6535-4725
Patients: 55-85 years old
Diagnostic: Early Alzheimer’s disease
Agent: Semaglutide
Once Daily Oral Administration
Enrollment: Closed
TauRx Therapeutics Ltd.
Protocol: TRx-237-039
Patients: <90 years old
Diagnostic: MCI/Early Alzheimer’s disease
Agent: TRx0237
Daily Oral Administration
Enrollment: Closed